GenMark to Sell 10 Million Shares in Public Offering | GenomeWeb

NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Tuesday that it intends to sell 10 million shares of its common stock in a public offering.

The Carlsbad, Calif.-based molecular diagnostics company did not price the offering or say how much in proceeds it anticipates raising. It said, though, that net proceeds will be used for R&D efforts to expand its menu and develop its NexGen System testing platform, as well as to expand its US and global commercial operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.